Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Retained Earnings (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Retained Earnings data on record, last reported at -$439.8 million in Q3 2025.

  • For Q3 2025, Retained Earnings rose 8.45% year-over-year to -$439.8 million; the TTM value through Sep 2025 reached -$439.8 million, up 8.45%, while the annual FY2024 figure was -$151000.0, 99.96% up from the prior year.
  • Retained Earnings reached -$439.8 million in Q3 2025 per STOK's latest filing, down from $96000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $96000.0 in Q2 2025 and bottomed at -$480.3 million in Q3 2024.
  • Average Retained Earnings over 4 years is -$210.7 million, with a median of -$245.4 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: plummeted 71509.2% in 2024, then soared 740.0% in 2025.
  • A 4-year view of Retained Earnings shows it stood at -$297.2 million in 2022, then crashed by 35.23% to -$401.8 million in 2023, then skyrocketed by 99.96% to -$151000.0 in 2024, then crashed by 291145.7% to -$439.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$439.8 million in Q3 2025, $96000.0 in Q2 2025, and -$104000.0 in Q1 2025.